IN8bio Files 8-K on Security Holder Rights & Financials
Ticker: INAB · Form: 8-K · Filed: Jun 4, 2025 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Jun 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, filing, financials
Related Tickers: IN8BIO
TL;DR
IN8bio filed an 8-K, expect updates on security holder rights and financials.
AI Summary
IN8bio, Inc. filed an 8-K on June 3, 2025, reporting material modifications to the rights of security holders and financial statements. The company, formerly known as Incysus Therapeutics, Inc., is incorporated in Delaware and has its principal executive offices in New York. The filing does not contain specific financial figures or details about the modifications.
Why It Matters
This filing indicates potential changes affecting IN8bio's security holders and provides an update on its financial reporting, which could impact investor decisions.
Risk Assessment
Risk Level: medium — The filing itself is procedural, but the nature of 'material modifications to rights of security holders' can introduce uncertainty.
Key Players & Entities
- IN8BIO, INC. (company) — Registrant
- Incysus Therapeutics, Inc. (company) — Former Company Name
- June 3, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- New York (location) — Address of Principal Executive Offices
- 001-39692 (identifier) — SEC File Number
FAQ
What specific material modifications were made to the rights of security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item, but the provided text does not detail the specific nature of these modifications.
What is the significance of filing 'Financial Statements and Exhibits' in this 8-K?
This indicates that IN8bio is providing updated financial information or exhibits as part of this filing, which is a standard requirement for certain corporate events or disclosures.
When was IN8bio, Inc. previously known as?
IN8bio, Inc. was formerly known as Incysus Therapeutics, Inc., with a date of name change on May 10, 2018.
Where are IN8bio, Inc.'s principal executive offices located?
The principal executive offices of IN8bio, Inc. are located at 350 5th Avenue, Suite 5330, New York, New York 10118.
What is the SEC file number for IN8bio, Inc.?
The SEC file number for IN8bio, Inc. is 001-39692.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 4, 2025 regarding IN8BIO, INC. (INAB).